Medication info

Janumet M Tablets 50/850 mg (Sitagliptin Phosphate/Metformin Hydrochloride)

Prescription medicationTabletOralExpired
Ingredient · strength
Sitagliptin Phosphate›62.04mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Samchundang Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablets
Packaging
30 tablets/box [(10 tablets/PTP) x 3]
Approval status
Expired

MFDS item code 201503337 · Approved 2015.05.29

This product's status changed to Expired on 2025.05.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this product should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This product is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this product should be based on the patient's current treatment regimen. 1. Patients not currently treated with metformin: For patients with no previous history of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this product 50/500 mg twice daily. The dose may be increased to 1 tablet of this product 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this product (see Precautions for Use, 2. Contraindications). 2. Patients treated with metformin: - The recommended initial dose of this product for patients who do not achieve adequate glycemic control with metformin monotherapy is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's existing metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this product may start at their existing doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this product is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should take into account the patient's blood glucose level and existing dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this product in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This product may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this product because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this product should be discontinued immediately. Patients with hepatic impairment This product should not be administered to patients with impaired liver function due to its metformin component (see Precautions for Use, 2. Contraindications).

Ingredients

Manufacturer
Samchundang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication helps patients with type 2 diabetes to better control their blood glucose levels. It is particularly appropriate to be used in combination with dietary and exercise therapies, as sitagliptin and metformin effectively enhance blood glucose control. This leads to improved management of blood sugar, thus assisting in diabetes treatment.

How to take

Adult dose

For antidiabetic therapy, the dose of this product should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This product is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this product should be based on the patient's current treatment regimen. 1. Patients not currently treated with metformin: For patients with no previous history of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this product 50/500 mg twice daily. The dose may be increased to 1 tablet of this product 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this product (see Precautions for Use, 2. Contraindications). 2. Patients treated with metformin: - The recommended initial dose of this product for patients who do not achieve adequate glycemic control with metformin monotherapy is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's existing metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this product may start at their existing doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this product is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should take into account the patient's blood glucose level and existing dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this product in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This product may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this product because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this product should be discontinued immediately. Patients with hepatic impairment This product should not be administered to patients with impaired liver function due to its metformin component (see Precautions for Use, 2. Contraindications).

Precautions

This medication contains sitagliptin and metformin, and is used in the treatment of diabetes. First, serious allergic reactions may occur during the use of this medication; if symptoms such as rash, hives, difficulty breathing, or swelling of the face or neck occur, discontinue use immediately and consult a physician. Additionally, acute pancreatitis, an inflammation of the pancreas, may rarely occur, so if sudden abdominal pain, nausea, vomiting, or fever occurs, immediate medical attention is required. The metformin component can rarely cause lactic acidosis, a serious metabolic disorder, which may present with symptoms such as muscle pain, difficulty breathing, fatigue, abdominal pain, or irregular heartbeat; if any of these symptoms occur, seek treatment immediately. This medication should not be used in patients with severely decreased kidney function, severe infections, dehydration, congestive heart failure, or anyone in unstable condition such as acute myocardial infarction. Particularly, if a radiological examination using iodinated contrast agents is planned, discontinue this medication 48 hours before the examination, and resume only after confirming that kidney function is normal. Women who are pregnant, may become pregnant, or are breastfeeding should not take this medication, and safety and efficacy in children under 18 years of age have not been established. Regular kidney function and blood tests should be carried out while on this medication, and periodic monitoring of vitamin B12 levels is also recommended. There is an increased risk of hypoglycemia if food intake is irregular or insufficient, vigorous exercise is undertaken, or if this medication is combined with other glycemic agents. If undergoing surgery, discontinue this medication 48 hours before the procedure and resume only after proper recovery of oral intake and confirmation of normal kidney function afterward. It is advisable to avoid alcohol consumption while taking this medication, as alcohol may increase the risk of lactic acidosis. If skin blisters or severe joint pain occur while using this medication, inform your physician immediately, who may need to discontinue treatment. This medication may interact with other drugs, so inform your physician or pharmacist about any other medications being taken. Finally, if any unusual symptoms arise while taking this medication, it is important to immediately consult an expert for appropriate measures.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 22 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • urticaria
  • cutaneous vasculitis
  • severe and disabling arthralgia
  • blistering dermatitis herpetiformis
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • vitamin B12 deficiency
  • dyspnea
  • unstable angina
  • dizziness
  • decreased appetite
  • dermatitis
  • weight loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air and moisture entry, and should be kept at room temperature between 1 and 30 degrees Celsius. This will help maintain the medication's effectiveness for a longer duration.

Appearance and packaging

Appearance

Pink oval film-coated tablets

Package unit

30 tablets/box [(10 tablets/PTP) x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.